Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging

Abdominal Imaging

Volumn 38, Issue 4, 2013, Pages 736-744

  Gatto, A ^a   De Gaetano, A M ^a   Giuga, M ^a   Ciresa, M ^a   Siciliani, L ^b   Miele, L ^a   Riccardi, L ^a   Pizzolante, F ^a   Rapaccini, G L ^a   Gasbarrini, A ^a   Giuliante, F ^a   Vecchio, F M ^a   Pompili, M ^a   Bonomo, L ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Dysplastic nodule; Hepatobiliary contrast agent; Hepatocellular carcinoma; Liver cirrhosis; Magnetic resonance imaging

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; DIAGNOSTIC IMAGING; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TISSUE DIFFERENTIATION;

AGED; BIOPSY, LARGE-CORE NEEDLE; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE ENHANCEMENT; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS;

EID: 84882272103     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-012-9950-y     Document Type: Article

References (28)

1. Amit S, Jorge AM (2008) Screening for hepatocellular carcinoma. Gastroenterol Hepatol (NY) 4(3):201-208
2. Hussain SM, Zondervan PE, IJzermans JN, et al. (2002) Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 22:1023-1036
3. Matsui O, Kadoya M, Kameyama T, et al. (1991) Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178:493-497
4. Bartolozzi C, Battaglia V, Bozzi E (2011) Hepatocellular nodules in liver cirrhosis: contrast-enhanced MR. Abdom Imaging 36:290-299
5. Caudana R, Morana G, Pirovano G, et al. (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 199:513-520
6. Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5-13
7. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. (2000) Evaluation of the Accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. Am J Roentgenol 175:1111-1120
8. Manfredi R, Maresca G, Baron RL, et al. (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704-710
9. Bruix J, Sherman M (2011) American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020-1022
10. International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22:983-993
11. International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658-664
12. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43-46
13. Perneger TV (1998) What's wrong with Bonferroni adjustments. BMJ 316:1236-1238
14. Spinazzi A, Lorusso V, Pirovano G, Kirchin M (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282-291
15. Kirchin MA, Pirovano G, Spinazzi A (1998) gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798-809
16. Cavagna FM, Maggioni F, Castelli PM, et al. (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780-796
17. Pena CS, Saini S, Baron RL, et al. (2001) Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial. Korean J Radiol 2(4):210-215
18. Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43(3):202-210
19. Bartolozzi C, Battaglia V, Bozzi E (2009) HCC diagnosis with liver-specific MRI-close to histopathology. Dig Dis 27:125-130
20. Kim TK, Lee KH, Jang HJ, et al. (2011) Analysis of gadobenate dimeglumine-enhanced MR Findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 259(3):730-738
21. Morana G, Grazioli L, Kirchin MA, et al. (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46(4):225-239
22. Tahir B, Sandrasegaran K, Ramaswamy R, et al. (2011) Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade? Clin Radiol 66(9):845-852
23. Matsui O (2004) Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 47(3-5):271-276
24. Matsui O, Kobayashi S, Sanada J, et al. (2011) Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36(3):264-272
25. Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247(2):311-329
26. Theise ND, Park YN, Kojiro M, et al. (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6(2):497-512
27. Kobayashi M, Ikeda K, Hosaka T, et al. (2006) Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 106(3):636-647
28. Borzio M, Fargion S, Borzio F, et al. (2003) Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 39(2):208-214